March 18, 2026 • 8 min read
Much has been said about the agreement between Mercosur and the European Union, often from the most obvious perspective: tariff reduction.
In healthcare, however, that view’s incomplete.
What’s unfolding isn’t simply a trade liberalization process. It’s a structural reconfiguration of how medical devices and pharmaceuticals enter Brazil.
And more importantly? Who captures value along the way.
The Starting Point: Inefficiency by Design
Today, the import structure in healthcare still carries significant inefficiencies.
European medical devices reach Brazil burdened by tariffs, high logistics costs, and long distribution chains. Pharmaceuticals, in addition to taxation, face further constraints related to intellectual property and regulatory requirements.
The outcome’s predictable: inflated prices and limited access.
What Changes with the Agreement—and What Doesn’t
With the agreement’s implementation, tariff reductions will occur gradually, with a more immediate impact on medical devices and equipment. These products are expected to become more competitive relatively quickly as tariffs are reduced and eventually eliminated.
Pharmaceuticals, however, follow a different trajectory.
Although tariffs will also decrease over time, market access will remain heavily influenced by non-tariff barriers, including regulatory approval by ANVISA, patent protections, and clinical data requirements.
In practical terms, this creates a clear distinction:
Medical devices respond quickly to tariff reductions.
Pharmaceuticals evolve more slowly, constrained by structural barriers.
Beyond Cost: Predictability and Access
Tariff reduction alone doesn’t transform a market.
The real impact? Predictability.
As cost structures become more stable and import dynamics clearer, new entry models begin to emerge, enabling more efficient alignment between supply and demand.
This is where the shift truly begins.
A New Supply Chain Logic
Traditionally, the flow’s been linear:
Manufacturer → Importer → Distributor → Hospital
This model fragments information, dilutes margins, and reduces efficiency.
As the agreement progresses and more integrated models evolve, this logic begins to shift toward a demand-driven, data-oriented, and coordinated structure.
This isn’t simply about removing intermediaries. It’s about redefining their roles.
Where Value Begins to Concentrate
Not all segments will benefit equally or at the same pace.
In the short term, the most significant value capture will occur in European medical devices. These products combine meaningful tariff impact, relatively lower regulatory complexity compared to pharmaceuticals, and faster adoption cycles.
Creating a more immediate return opportunity for those who can efficiently structure market entry and distribution.
Hospital equipment and diagnostic solutions follow closely, driven by high ticket size and recurring demand dynamics.
Pharmaceutical opportunities, while relevant, are more selective. Specialty and niche products tend to benefit first, given their reliance on targeted access rather than scale alone.
The Most Common Mistake: Focusing Only on Tariffs
A common misconception? That the agreement creates opportunity.
In reality, it accelerates opportunities that already exist and favors those who are prepared to capture them.
Focusing solely on tariff reduction means looking at the effect, not the underlying shift.
The real transformation lies in the reconfiguration of the supply chain.
What This Means in Practice
In the coming years, competitive advantage won’t be defined solely by product or price.
It’ll depend on the ability to integrate three critical elements:
Regulation. Market access. Distribution.
Companies that align these pillars strategically will gain a clear advantage—not only in entering the market, but in establishing long-term relevance.
A Window That Won’t Remain Open
The agreement creates a critical timing window.
In the early years, while tariff reductions are still unfolding and competition hasn’t fully adapted, there’s an opportunity to capture higher margins and secure positioning.
Over time? This advantage will narrow as the market matures.
Conclusion: This Isn’t About Trade—It’s About Positioning
The Mercosur–European Union agreement doesn’t just reshape trade.
It reshapes who leads market access.
In healthcare, leadership won’t be defined by who has the best product alone, but by who can turn complexity into strategy and strategy into execution.
Because ultimately, this isn’t just about lowering costs.
It’s about controlling how and by whom the market is accessed.
Find out more about BPO in RA!
*Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br
